Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2013. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by several executives on December 10, 2013, through the Company's ShareReward Plan. The transactions involved purchases at a price of 1594.287 pence per share. The acquisitions consisted of both personal contributions and matching company contributions.
- Sir Andrew Witty: Acquired 7 shares (personal) and 7 shares (company match).
- Mr S Dingemans: Acquired 8 shares (personal) and 8 shares (company match).
- Mr S M Bicknell: Acquired 7 shares (personal) and 7 shares (company match).
- Mr R G Connor: Acquired 7 shares (personal) and 7 shares (company match).
- Mr D S Redfern: Acquired 7 shares (personal) and 7 shares (company match).
- Ms C Thomas: Acquired 7 shares (personal) and 7 shares (company match).
- Mr P C Thomson: Acquired 7 shares (personal) and 7 shares (company match).
- Dr P J T Vallance: Acquired 8 shares (personal) and 8 shares (company match).
- Ms E Walmsley: Acquired 8 shares (personal) and 8 shares (company match).
- Mrs V A Whyte: Acquired 7 shares (personal) and 7 shares (company match).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the share transactions noted above in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1594.287 pence per Ordinary Share on December 10, 2013.
- Confirm the total number of shares acquired by each listed executive under the ShareReward Plan.
- Review the company's broader annual report (Form 20-F) for comprehensive financial performance data, as this filing contains none.